Nontuberculous Mycobacterial Infections - Global Strategic Business Report

The global market for Nontuberculous Mycobacterial Infections was estimated at US$14.0 Billion in 2024 and is projected to reach US$18.3 Billion by 2030, growing at a CAGR of 4.5% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Nontuberculous Mycobacterial Infections market.

Global Nontuberculous Mycobacterial Infections Market - Key Trends & Drivers Summarized

Why Are Nontuberculous Mycobacteria (NTM) Gaining Clinical Attention?

Infections caused by nontuberculous mycobacteria have become a growing concern due to increasing identification in patients with chronic lung conditions, such as bronchiectasis, COPD, or cystic fibrosis. These environmental bacteria are found in soil, water systems, and biofilms and can cause persistent, difficult-to-treat pulmonary infections. Increased awareness among pulmonologists, coupled with more frequent use of high-resolution imaging and sputum cultures, has led to a rise in confirmed diagnoses globally.

NTM infections can also occur in skin and soft tissue, lymph nodes, and disseminated in immunocompromised individuals. Clinical recognition has improved through updated guidelines that encourage suspicion in patients with unexplained respiratory symptoms and persistent nodular or bronchiectatic changes on CT scans. This heightened vigilance has driven more systematic screening and laboratory testing, making infection rates appear to rise even as actual incidence increases.

How Are Diagnostic and Treatment Innovations Improving Patient Outcomes?

Diagnostic methods for NTM are evolving beyond traditional culture-based techniques. Molecular assays, such as PCR and line probe assays, enable faster species identification and antimicrobial resistance detection. This precision allows clinicians to tailor antibiotic regimens early in therapy, improving treatment success. Research into novel biomarkers and advanced imaging techniques is helping differentiate active infection from colonization, addressing a key challenge in clinical management.

Therapeutic approaches now combine multiple antimycobacterial agents administered for long durations, often exceeding 12 months. Newer drugs-such as inhaled amikacin liposome suspension and oxazolidinones-offer targeted therapy with reduced systemic toxicity. Adjunct treatments, including airway clearance devices and pulmonary rehabilitation, support lung function and treatment adherence. Clinical trials are testing immunomodulatory agents to boost host response and reduce bacterial burden, with promising early-stage results.

What Care Models and Management Strategies Are Emerging?

Management of NTM infections increasingly relies on multidisciplinary care teams that include pulmonologists, infectious disease specialists, radiologists, and pharmacists. Comprehensive care hubs offer coordinated diagnostics, treatment initiation, monitoring of drug interactions, side effects, and adherence support. Telehealth tools and digital reminders are also being used to monitor long-term treatment compliance and track adverse effects remotely.

Patient education and support groups are gaining importance in treatment frameworks. Sustained patient engagement through digital platforms helps manage the emotional and logistical challenges of prolonged therapy. Health systems are beginning to develop NTM-specific registries that collect data on treatment outcomes, species distribution, and regional epidemiology, enabling more informed decision-making and benchmarking.

Growth in the nontuberculous mycobacterial infections market is driven by several factors.

Increasing prevalence of NTM infections, especially among aging and immunocompromised populations, is expanding patient pools and clinical awareness. Advances in molecular diagnostics are enabling faster and more accurate species identification and resistance profiling. Introduction of novel antimycobacterial drugs and inhaled delivery systems is offering alternatives to standard therapies. Emergence of multidisciplinary care models supported by telehealth and digital adherence tools is improving long-term treatment success. Finally, formation of patient registries and growing research into NTM epidemiology and therapeutics are fostering treatment innovation and adoption of best practices by healthcare providers.

Scope Of Study:

The report analyzes the Nontuberculous Mycobacterial Infections market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments: Drug Type (Clarithromycin, Azithromycin, Rifampin, Rifabutin, Other Drug Types); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Clarithromycin segment, which is expected to reach US$7.1 Billion by 2030 with a CAGR of a 5.6%. The Azithromycin segment is also set to grow at 2.9% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $3.8 Billion in 2024, and China, forecasted to grow at an impressive 8.4% CAGR to reach $3.8 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Nontuberculous Mycobacterial Infections Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Nontuberculous Mycobacterial Infections Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Nontuberculous Mycobacterial Infections Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Abbott Laboratories, Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, BioMarin Pharmaceutical Inc. and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 36 companies featured in this Nontuberculous Mycobacterial Infections market report include:

• Abbott Laboratories
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bayer AG
• BioMarin Pharmaceutical Inc.
• Bristol Myers Squibb
• Cipla Ltd.
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• GlaxoSmithKline PLC
• Insmed Incorporated
• Janssen (Johnson & Johnson)
• MannKind Corporation
• Merck & Co. Inc.
• Novartis AG
• Paratek Pharmaceuticals Inc.
• Pfizer Inc.
• RedHill Biopharma Ltd.
• Sanofi S.A.
• Spero Therapeutics Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Vertex Pharmaceuticals Inc.
• Zydus Lifesciences Ltd.

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

• Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
• Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
• Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
• Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
• Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
• Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
• Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.